PRIVATE MARKETS
JonesTrading Leads $81.3m IPO for Biopharmaceutical Company Vogenx
Shares priced at the top of their range as the metabolic disease specialist began trading on the Nasdaq Capital Market under the ticker VOGX.
JonesTrading Institutional Services LLC has announced that it served as sole book-running manager for the $81.3 million initial public offering of Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for serious diseases associated with dysfunctions in human metabolism. The offering consisted of 6,250,000 shares of Vogenx common stock at a public offering price of $13.00 per share, at the high end of the proposed range, with all shares offered by Vogenx.
Trading begins on Nasdaq
Gross proceeds to Vogenx from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $81.3 million. Vogenx's common stock began trading on the Nasdaq Capital Market on 12 August 2026 under the ticker symbol "VOGX," with the offering closing on 13 August 2026.
Comments from Jones and Vogenx
Alan Hill, Chief Executive Officer of JonesTrading, said: "We are proud to have partnered with Vogenx on this important milestone. This transaction reflects the continued growth of our investment banking and capital markets platform and our ability to deliver thoughtful, high-quality execution for innovative healthcare companies accessing the public markets." Moe Cohen, Head of Investment Banking at Jones, added: "The success of this offering underscores the strength of Jones's relationships across the fundamental biotech investment community. Our ability to connect compelling companies with sophisticated, long-term healthcare investors was an important component of the transaction."
Vogenx Chief Executive James Green said: "This transaction is a milestone that represents years of hard work from a dedicated team. We are now well-capitalized to further the development of therapeutics for the treatment of diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis." JonesTrading is a full-service investment banking firm providing capital markets, mergers and acquisitions, and strategic advisory services to corporate clients.